Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

被引：0
|
作者：
Fang, Y. [1 ]
Pan, H. [1 ]
Shou, J. [2 ]
Hong, W. [3 ]
Yang, X. [4 ]
Zhu, D. [5 ]
Zhou, Y. [6 ]
Lan, F. [7 ]
Rao, C. [8 ]
Chen, J. [9 ]
机构：
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[4] First Hosp Jiaxing, Jiaxing, Peoples R China
[5] Jinhua Municipal Cent Hosp, Jinhua, Zhejiang, Peoples R China
[6] Cent Hosp Lishui City, Lishui, Peoples R China
[7] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[8] Univ Chinese Acad Sci, Hwa Mei Hosp, Ningbo, Peoples R China
[9] Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Anlotinib; NSCLC; anti-angiogenesis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P86.22
引用
收藏
页码：S682 / S682
页数：1
相关论文
共 50 条
  • [21] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Valerie Israel
    Scott T. Tagawa
    Terry Snyder
    Susan Jeffers
    Derek Raghavan
    Investigational New Drugs, 2004, 22 : 291 - 297
  • [22] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Israel, V
    Tagawa, ST
    Snyder, T
    Jeffers, S
    Raghavan, D
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 291 - 297
  • [23] A Phase II Study of Weekly Docetaxel-Cisplatin As First-Line Treatment for Advanced Non-small Cell Lung Cancer
    Binder, Daniel
    Hackenthal, Matthias
    Graseck, Lutz
    Schweisfurth, Hans
    Schaeper, Christoph
    Kruell, Matthias
    Temmesfeld-Wollbrueck, Bettina
    Suttorp, Norbert
    Suttorp, Thomas
    Beinert, Thomas
    Hellriegel, Klaus-Peter
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : 1144 - 1147
  • [24] A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer
    Giannakakis, T
    Kakolyris, S
    Theodoropoulos, E
    Kouroussis, C
    Michailakis, E
    Papadouris, S
    Tsitoura, M
    Kalbakis, K
    Souglakos, J
    Agelaki, S
    Vardakis, N
    Georgoulias, V
    ANTICANCER RESEARCH, 2002, 22 (6B) : 3743 - 3748
  • [25] Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors.
    Leighl, NB
    Laurie, SA
    Knox, JJ
    Ellis, PM
    Shepherd, FA
    Burkes, RL
    Vincent, M
    Pond, GR
    Zwiebel, JA
    Moore, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 683S - 683S
  • [26] Phase 2 study of bortezomib±docetaxel in advanced non-small cell lung cancer (NSCLC)
    Fanucchi, M
    Fossella, F
    Fidias, P
    Natale, R
    Belt, R
    Govindan, R
    Raez, L
    Schiller, J
    Kashala, O
    Kelly, K
    LUNG CANCER, 2005, 49 : S30 - S30
  • [27] Docetaxel in advanced non-small cell lung cancer
    Wakelee, H
    Ramalingam, S
    Belani, CP
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 13 - 24
  • [28] Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Kimura, Tatsuo
    Mitsuoka, Shigeki
    Kyoh, Shigenoir
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kodama, Toyoki
    Ichimaru, Yukikazu
    Yana, Takashi
    Hirata, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 371 - 375
  • [29] Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer
    Ishimoto, Osamu
    Sugawara, Shunichi
    Inoue, Akira
    Ishida, Takashi
    Munakata, Mitsuru
    Koinumaru, Sadahiro
    Hasegawa, Yukihiro
    Suzuki, Toshiro
    Miki, Hiroshi
    Saijo, Yasuo
    Nukiwa, Toshihiro
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) : 979 - 983
  • [30] Front-line treatment of advanced non-small cell lung cancer with Docetaxel and Irinotecan: A multicenter phase II trial
    Ziotopoulos, P.
    Mylonaki, E.
    Boukovinas, J.
    Agelidou, M.
    Chandrinos, V.
    Zachariadis, E.
    Varthalitis, J.
    Ardavanis, A.
    Christopoulou, A.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
12345